Nanobiotix Updates Share Capital and Voting Rights as of June 30, 2026
at www.tipranks.com (Fri, 31-Jul 5:27 PM)
Nanobiotix’s NBTXR3 Achieves 85.7% Response Rate in Phase 2 Lung Cancer Trial—Early Data Signals Potential Shift in Standard of Care
Market Chameleon (Mon, 18-May 8:57 AM)
